CIM
MYGN icon

Contrarius Investment Management’s Myriad Genetics MYGN Stock Holding History

Contrarius Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-248,090
Closed -$7.33M – 66
2018
Q1 		$7.33M Buy
248,090
+12,355
+5% +$418K 0.35% 39
2017
Q4 		$8.1M Sell
235,735
-72,328
-23% -$2.44M 0.4% 36
2017
Q3 		$11.1M Sell
308,063
-25,716
-8% -$733K 0.65% 36
2017
Q2 		$8.63M Sell
333,779
-182,142
-35% -$3.87M 0.58% 30
2017
Q1 		$9.91M Buy
515,921
+113,486
+28% +$2.01M 0.64% 29
2016
Q4 		$6.71M Buy
402,435
+134,664
+50% +$2.44M 0.5% 27
2016
Q3 		$5.51M Buy
267,771
+177,263
+196% +$4.5M 0.41% 38
2016
Q2 		$2.77M Sell
90,508
-493,696
-85% -$17.2M 0.24% 45
2016
Q1 		$21.9M Sell
584,204
-68,084
-10% -$2.57M 1.94% 15
2015
Q4 		$28.2M Sell
652,288
-95,573
-13% -$4.04M 2.65% 12
2015
Q3 		$28M Sell
747,861
-29,972
-4% -$1.06M 2.77% 12
2015
Q2 		$26.4M Buy
777,833
+245,900
+46% +$8.36M 2.06% 18
2015
Q1 		$18.8M Buy
+531,933
New +$19M 1.51% 19

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Contrarius Investment Management's MYGN Position: Q2 2018 in Review

Contrarius Investment Management sold out of Myriad Genetics (MYGN) in Q2 2018, closing a stake of 248,090 shares — an estimated $7.33M sold.

Contrarius Investment Management first reported a position in MYGN in Q1 2015 and held it in 13 quarters. The position peaked at $28.2M in Q4 2015. 258 funds tracked by Wall St. Rank hold MYGN as of Q2 2018.

  • Contrarius Investment Management reported no remaining Myriad Genetics position as of Q2 2018 after selling out during the quarter.
  • Contrarius Investment Management sold 248,090 Myriad Genetics shares in Q2 2018, an estimated $7.33M.
  • Contrarius Investment Management first reported a position in Myriad Genetics in Q1 2015 and held it in 13 quarters.
  • Contrarius Investment Management's Myriad Genetics position peaked at $28.2M in Q4 2015.
  • 258 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2018.

Based on Contrarius Investment Management's 13F filing for Q2 2018, filed 8 Aug 2018.